Abstract
Debulking of left ventricular septal mass is typically accomplished using surgical myectomy, which is morbid, or using transcoronary alcohol septal ablation, which can result in geographic miss and occasional catastrophic nontarget coronary injury. The authors developed and tested operational parameters in vitro and vivo for a device to accomplish transvenous intraseptal radiofrequency ablation to reduce ventricular septal mass using a technique derived from mitral cerclage, which the authors call cerclage ablation. Cerclage ablation appeared feasible in vitro and safe and effective in vivo. Cerclage ablation is an attractive new approach to debulk the interventricular septum in obstructive hypertrophic cardiomyopathy. These data support clinical investigation.
Abstract as published in JACC. Basic to translational science, 2020;5(10):988-998, reproduced without changes (source: PubMed PMID 33145462). Read the full article on the publisher's site.
Related publications
Bioengineering 2025 · Preclinical
Gradual Temperature Rise in Radiofrequency Ablation: Enhancing Lesion Quality and Safety in Porcine Myocardial Tissue
View detailsBiomedicines 2024 · Clinical
